Introduction {#s1}
============

Pathogenesis of Acne Vulgaris {#s1_1}
-----------------------------

Acne vulgaris is a common skin disease affecting the vast majority of adolescents and a significant proportion of young adults. Approximately 85% of the population suffers from acne vulgaris at some point in their lives ([@B26]). Acne negatively impacts self-esteem, self-confidence, and social life as it specifically affects the skin of the face, the chest, and the back---areas where the pilosebaceous gland concentration is the highest ([@B32]; [@B33]). Four processes characterize acne pathogenesis: 1) follicular hyperkeratinization, 2) excess of sebum, 3) colonization of *Cutibacterium acnes*, and 4) inflammation and immune response ([@B34]). *C. acnes* is a Gram-positive aero-tolerant anaerobic bacteria found in the sebaceous follicle. The oxygen-poor area formed by the lipid-rich obstructed follicle makes an ideal environment for the bacteria to proliferate. Other factors such as hormonal fluctuations or imbalance, stress, and pollution can also increase inflammation by providing a suitable environment for *C. acnes* growth ([@B1]).

Current Treatment and Limitations {#s1_2}
---------------------------------

Current treatments for acne vulgaris include the use of topical antibiotics and/or chemical peeling agents. Treatments can also include daily oral antibiotics, retinoids, or hormones. In the United States, topical agents predominantly prescribed in the treatment of mild to moderate acne are composed of retinoids such as differin, tazorac, or retin-A, in combination with antibiotics such as clindamycin and erythromycin ([@B33]). Benzoyl peroxide and salicylic acid are non-antibiotic therapies frequently added to creams to decrease the risk of developing antibiotic resistance and to reduce inflammation ([@B31]). The most commonly used oral therapies include the tetracyclines (tetracycline, minocycline, and doxycycline), trimethoprim/sulfamethoxazole, and macrolides (erythromycin and azithromycin) ([@B16]).

A major disadvantage of current treatments is that daily intake of antibiotics places great selective pressure on bacteria to develop multidrug resistance ([@B37]). Many countries have reported increasing resistance of *C. acnes* strains to topical macrolides ([@B39]). Application of an active antibiotic gel increased resistance to erythromycin after only 12 weeks of treatment ([@B20]). The treatment of an individual's acne can also have unintended effects on the microbiome, resulting in antibiotic resistance and proliferation of opportunistic pathogens elsewhere in the body. Margolis *et al.* reported that development of upper respiratory tract infections and pharyngitis was more likely in patients receiving oral antibiotics ([@B17]; [@B18]). In light of the growing concern for increasing antibiotic resistance of *C. acnes* and other bacteria due to antibiotic use in acne treatment, alternative therapies are urgently needed.

Ethnopharmacological Relevance of *Callicarpa americana* {#s1_3}
--------------------------------------------------------

Ethnobotany is the study of plants used in different cultures, and it is a valuable framework from which to pursue drug discovery ([@B5]). Botanical therapies are a mixture of many active and non-active components, thus potentially having several modes of action, both direct and synergistically. The Quave Natural Product Library (QNPL) is a chemical library composed of over 1,900 plant extracts derived from 600 plant and fungal species, largely representing plants used in the traditional treatment of infectious and inflammatory skin disease. A screen of the QNPL against *C. acnes* revealed the growth inhibitory bioactivity of a crude leaf extract from *Callicarpa americana* L. (Lamiaceae), a native Southeastern American shrub. The *Callicarpa* genus has a rich history of use in traditional medicine and is characterized by the presence of biologically active terpenoids, such as monoterpenoids and diterpenoids ([@B11]). The fruits are the most striking elements of the plants in this genus---hence the genus name '*Callicarpa*,' meaning "beautiful fruit," and the common name, 'Beauty Berry.' The Alabama, Choctaw, Creek, Koasati, Seminole, and other Native American tribes used preparations of the roots, leaves, and branches for various medicinal purposes, including to treat fevers, stomachaches, and skin cancers ([@B29]; [@B9]).

Interestingly, *Callicarpa* species are also a key component of Asian traditional medicines ([@B36]). *C. arborea* Roxb. was traditionally used in India to heal cuts and wounds, and *C. tomentosa* Lam. was used to cure boils and eczema. In China, *C. macrophylla* Vahl, *C. pedunculata* R.Br., and *C. cathayana* C.H.Chang were applied to the skin to heal burns and bleeds ([@B9]), highlighting the potential effectiveness of the *Callicarpa* genus to treat skin diseases ([@B8]; [@B2]).

*Callicarpa americana* as a Source of Antimicrobial Therapies for Acne {#s1_4}
----------------------------------------------------------------------

Few studies have reported the bioactivity of the species *C. americana*. Three diterpenes (genkwanin, 16ξ-hydroxycleroda-3,13-dien-15,16-olide, and 2-formyl-16ξ-hydroxy-3-A-norcleroda-2,13-dien-15,16-olide) were isolated from the combined fruits, leaves, and twigs (fruiting branches) of *C. americana* and exhibit activity against human cancer cell lines ([@B10]). Intermedeol and callicarpenal (3,14,15,16-tetranorclerodane) compounds were found in essential oils from the leaves and acted as effective deterrents of *Aedes stephensi* and *Aedes aegypti* mosquitos ([@B3]). Research focused on other species within the same genus, and leaf extracts of *C. longifolia* Lam. in a gel preparation were recently found to exhibit antibacterial and wound healing effects on rabbit skin ([@B28]). A retinoid-containing gel in combination with a *C. nudiflora* Hook. & Arn. extract tablet was used in a clinical research study on acne vulgaris and was demonstrated to be more effective than the gel alone ([@B40]). These studies highlight the need for further research on *C. americana* extracts. In the present work, we demonstrate the promising growth inhibitory activity of *C. americana* on *C. acnes*.

Materials and Methods {#s2}
=====================

Plant Collection and Identification {#s2_1}
-----------------------------------

Fresh leaves of *C. americana* were harvested from wild populations in Atlanta, GA, in June and August 2017. Voucher specimens ([**Table 1**](#T1){ref-type="table"}) were deposited at the Emory University Herbarium (GEO), and species identity was confirmed by botanist Tharanga Samarakoon, Ph.D. Specimens were digitized and are available for viewing on the SERNEC portal ([@B25]). Bulk plant material was dried in a dehumidification chamber and then ground into a fine powder through a 2-mm mesh with a Thomas Scientific Wiley Mill (Swedesboro, NJ). Retention vouchers of dried and ground material were prepared for future reference and stored in The Quave Research Laboratories at Emory University.

###### 

List of *Callicarpa americana* specimens harvested from wild populations in Atlanta, GA.

  --------------------------------------------------------------------------------------------------------------------------
  GEO accession number   Collection date   Collection location                                        Location coordinates
  ---------------------- ----------------- ---------------------------------------------------------- ----------------------
  22044                  June 26, 2017     Hahn Wood, Emory University; USA, Georgia, DeKalb County   33.8036944440 N,\
                                                                                                      −84.3230833330 W

  22204                  Aug. 11, 2017     Coralwood Centre School; USA, Georgia, DeKalb County       33.8281800000 N,\
                                                                                                      −84.2872430000 W

  22205                  Aug. 11, 2017     Coralwood Centre School; USA, Georgia, DeKalb County       33.8281800000 N,\
                                                                                                      −84.2872430000 W
  --------------------------------------------------------------------------------------------------------------------------

Voucher specimens of all populations harvested were collected and deposited at the Emory University Herbarium (Index Herbariorum Code: GEO). Digitized specimens are available for viewing online through the SERNEC portal ([@B25]).

Preparation of Extracts {#s2_2}
-----------------------

Dry, ground plant biomass was double macerated in 95% ethanol at a 1:10 ratio (*w*/*v*) for 72 h of maceration with daily agitation. The liquid was then decanted and vacuum filtered, then concentrated by rotary evaporation at ≤40°C. Extracts were redissolved in dH~2~O, shell frozen in a dry ice--acetone bath, and lyophilized overnight on a Labconco FreeZone 2.5 Lyophilizer (Kansas City, MO). Dry crude extract (Extract ID: 649) was scraped into scintillation vials and stored at −20°C until microbiological testing, at which time they were dissolved in DMSO to a stock concentration of 10 mg ml^−1^.

Fractionation Strategy {#s2_3}
----------------------

The crude extract (649) was partitioned against hexanes, ethyl acetate, *n*-butanol, and water following a modified Kupchan scheme. Subsequently, the ethyl acetate partition (649C) was determined to be the most active partition by antimicrobial bioassays and was further fractionated *via* flash chromatography. The full fractionation strategy is detailed in [**Figure 1**](#f1){ref-type="fig"}.

![Extraction and fractionation strategy for *C. americana* dried leaves.](fphar-10-01206-g001){#f1}

Briefly, to prepare the sample, 15.36 g of the extract was dissolved in methanol, Celite was added at a 1:4 ratio (*w*/*w*), the mixture was concentrated *in vacuo*, and the dry preparation was loaded into a Teledyne solid-phase load cartridge. A 330-g RediSep Rf Gold Silica column was used with the CombiFlash Rf+ (Teledyne ISCO) flash chromatography system. Three mobile phases---hexanes, ethyl acetate, and methanol---were used to perform the separation ([**Table 2**](#T2){ref-type="table"} and [**Figure 2**](#f2){ref-type="fig"}). The resulting tubes were combined into 31 fractions, dried *in vacuo*, lyophilized, scraped into scintillation vials, and then stored at −20°C until testing.

###### 

Gradient table for the flash chromatography separation of extract 649C.

  Minutes   \% Hexane   \% Ethyl Acetate   \% Methanol
  --------- ----------- ------------------ -------------
  0         100         0                  0
  4.4       100         0                  0
  8.2       99          1                  0
  12        98          2                  0
  15.8      96          4                  0
  19.6      91.9        8.1                0
  24.3      85.4        14.9               0
  38.9      68.1        31.9               0
  54.3      35.9        641                0
  69.8      0           100                0
  88.2      0           100                0
  88.4      0           100                0
  92.2      0           99                 1
  96        0           98                 2
  99.8      0           96                 4
  103.6     0           92                 8
  107.4     0           84                 16
  111.2     0           70                 30
  129.7     0           70                 30
  133.3     0           0                  100
  146.6     0           0                  100

The flow rate for the 330-g RediSep Rf Gold Silica column was 200 ml min^−1^.

![Flash chromatogram of 649C fraction. A 330-g Gold Silica column was loaded with 15.36 g of the 649C fraction. Three mobile phases--- hexanes, ethyl acetate, and methanol---were used to perform the separation. The blue line details the percent of ethyl acetate mobile phase. In total, 31 fractions were decided based on the chromatogram, with each peak being assigned to a unique fraction if possible. Absorbance of the extract is read on the *left axis* (*red*, *orange*, and *pink lines* for three wavelengths: 254 nm, 320 nm, and total absorbance of 200--780 nm, respectively). The *x-axis* corresponds to column volumes (CV) with a total run length of 66.3 CV.](fphar-10-01206-g002){#f2}

Antibacterial Testing {#s2_4}
---------------------

### Bacterial Strains and Cultures {#s2_4_1}

Extracts were first tested against a *C. acnes* isolate obtained from the American Type Culture Collection (strain ATCC6919). Based on these results, the most active fractions and their parent extracts were tested for growth inhibitory activity in nine additional clinical isolates of *C. acnes*; strain and source details are provided in [**Table 3**](#T3){ref-type="table"}. All bacteria were streaked onto tryptic soy agar (TSA) plates supplemented with 5% sheep blood (Hardy). Plates were incubated at 37°C until individual colonies were visible (72 h for most isolates and 120 h for the slowest growers) before individual colonies were transferred into Brain Heart Infusion broth supplemented with 1% dextrose (BHId). Liquid cultures were incubated for an additional 72 h before preparation of a working culture for biological assays. An EZ Anaerobe Chamber and GasPak EZ Anaerobe (BD) container sachets were used to create the anaerobic conditions required for *C. acnes* growth.

###### 

*C. acnes* strain details.

  Strain ID                 Strain genotype   Type of isolate     Body site
  ------------------------- ----------------- ------------------- ---------------------
  ATCC6919                  --                Laboratory strain   Facial acne
  B104.1                    Ribotype 3        Clinical isolate    Nasal microcomedone
  B104.2                    Ribotype 3        Clinical isolate    Nasal microcomedone
  B104.4                    Ribotype 3        Clinical isolate    Nasal microcomedone
  B104.5                    Ribotype 3        Clinical isolate    Nasal microcomedone
  B104.6                    Ribotype 1        Clinical isolate    Nasal microcomedone
  B104.7                    Ribotype 1        Clinical isolate    Nasal microcomedone
  B104.8                    Ribotype 3        Clinical isolate    Nasal microcomedone
  HL013PA1; HM-497; EU-09   --                Clinical isolate    --
  HL030PA1; HM-504; EU-16   --                Clinical isolate    --

Clinical isolates B104.1 to B104.8 were obtained from Dr. Laura Marinelli ([@B19]). Clinical isolates EU-09 and EU-16 were obtained through BEI Resources, NIAID, NIH as part of the Human Microbiome Project.

-- indicates unknown information from the strain providers.

### Growth Inhibition Assays {#s2_4_2}

As no Clinical and Laboratory Standards Institute (CLSI) guidelines for MIC testing in *C. acnes* have been published, we followed a previously described microtiter broth method ([@B21]). Liquid cultures were standardized to an optical density of 0.05 at 590 nm (OD~590nm~), which corresponds to 5 × 10^7^ CFU ml^−1^, using a Cytation-3 multimode plate reader (BioTek). This was further confirmed by plate counts. BHId was used for adjusting the final inoculum density.

The growth inhibition assay was performed in a sterile 96-well plate (Falcon 351172) in a total well volume of 200 µL. The dose tested ranged from 0.125 to 64 μg ml^−1^ for ATCC6919 and from 2 to 64 μg ml^−1^ for all other clinical isolates. Negative controls (no treatment and DMSO vehicle treatment), positive control (clindamycin treatment), and a media control (BHId alone) were included, and all treatments were conducted in triplicate and repeated on two separate days. A first OD~600nm~ determination was conducted immediately following plate setup, prior to a 72-h incubation period at 37°C in an anaerobe chamber. A second OD~600nm~ determination was taken 72 h post-inoculation, and the final percent inhibition of growth was determined following a previously reported formula, which takes into account the effect of the extract color ([@B24]). The IC~50~ and MIC are the minimal concentrations to inhibit at least 50% and 90% of the growth, respectively.

### Biofilm Eradication {#s2_4_3}

Liquid cultures were standardized to an optical density at 590 nm (OD~590nm~) of 0.05, which corresponds to 5 × 10^7^ CFU ml^−1^, and pipetted into a 96-well tissue culture plate (TPP92097). After a 24-h incubation period at 37°C in an anaerobic chamber, the media was gently removed using a single-channel micropipette without disturbing the biofilm. Fresh BHId and treatment was added to each well. The plate was incubated for an additional 24 h at 37°C in an anaerobe chamber. The media was gently removed before fixing the biofilms in two steps: adding 100% ethanol to each well, removing it, and then heat fixing at 60°C for 60 min. Crystal violet was then added to each well for 5 min to stain the biofilms and was subsequently gently rinsed out under tap water. Plates were dried overnight, then a solution of 2.5% Tween 80 in ethanol was added to elute the stain for 15 min, the eluent transferred to a new 96-well plate, and an OD~595nm~ obtained to determine total biofilm mass in each well. The minimal biofilm eradication concentration (MBEC~50~) was defined as the minimal concentration of extract required to eradicate at least 50% of the preformed biofilm.

Mammalian Cytotoxicity Assay {#s2_5}
----------------------------

Mammalian cytotoxicity of extracts was assessed using human keratinocytes (HaCaTs) and a lactate dehydrogenase (LDH) test kit (G-Biosciences, St. Louis, MO) as previously described ([@B23]). Extracts were sterile-filtered with 0.2-µm syringe filters and tested at a concentration range of 2--1024 μg ml^−1^. Percent DMSO (*v*/*v*) in the wells was \<2% for all tests.

Chemical Characterization {#s2_6}
-------------------------

### LC-FTMS Analysis {#s2_6_1}

Liquid chromatography--Fourier transform mass spectrometry (LC-FTMS) was performed on 649C fractions using a Shimadzu SIL-ACHT (Columbia, MD) and Dionex (San Jose, CA) 3600SD HPLC pump. The stationary phase was a Phenomenex Kinetex C18 150 . 2.1 mm, 2.5 μm with guard column at room temperature. Mobile phases were Optima LC/MS (Fisher Scientific, Waltham, MA) consisting of (A) 0.1% formic acid in water (B) and 0.1% formic acid in methanol at a flow rate of 0.15 ml/min. The gradient profile consisted of initial conditions of 70:30 A/B which was held until 2.6 min., then a linear gradient applied until 5:95 A/B was reached at 52.7 min---this was held until 61.6 min---then a step gradient applied to 0:100 A/B, which was held until 70.4 min, and then the column returned to initial conditions prior to the next injection. A 20-μl injection of each fraction was applied onto the column. The chromatography was monitored at 190--600 nm by a Dionex DAD detector. The MS data was acquired in MS^1^ mode scanning a *m*/*z* of 150--1,500 on a Thermo Scientific LTQ-FT Ultra MS in positive ESI mode and processed with Thermo Scientific Xcalibur 2.2 SP1.48 software (San Jose, CA). The capillary temperature was 275.0°C, sheath gas of 40, source voltage and current of 5.0 kV and 100.0 μA, and capillary voltage of 29.0 V.

Putative formulas and compounds were determined for peaks of the bioactive fractions of 649C with greater than 1% relative abundance by area in the MS total ion chromatograph (TIC). Scifinder (Chemical Abstracts Service) was searched in July 2019 to identify putative matches. The (M+1)^+^ from the MS data was used to calculate the accurate mass of the parent ion and the databases searched for small molecules from the genus *Callicarpa* within ±1.0 Da. The molecular formulas of the hits were compared to empirical formulas derived from the experimental MS data. Database hits that matched the experimentally calculated empirical formula, ± 10 ppm, were evaluated further. Publications on the remaining small molecules were reviewed and the presence of the compound in the genus was verified. The resulting putative compound matches are in [**Table 5**](#T5){ref-type="table"}. Only an empirical formula is reported for ions that do not have a match in the database.

Results {#s3}
=======

Growth Inhibitory Activity Against *P. acnes* {#s3_1}
---------------------------------------------

Growth inhibitory effects of the crude extract and partitions of *C. americana* leaves were determined using a static MIC assay. The initial screen was performed on ATCC6919 and demonstrated that the ethyl acetate partition (649C) was the most effective inhibitor of *C. acnes* growth with an IC~50~ value of 32 μg ml^−1^. 649C was subjected to flash chromatography to yield 31 fractions. Eight out of the 31 fractions exhibited 100% growth inhibition at 64 μg ml^−1^ against ATCC6919 ([**Figure 3**](#f3){ref-type="fig"}). Dose-dependent growth inhibition of the most active fractions was then conducted on ATCC6919 as well as nine other clinical isolates of *C. acnes* ([**Figures 4**](#f4){ref-type="fig"} and [**5**](#f5){ref-type="fig"}). Growth inhibitory activity was observed for each of the 10 isolates of *C. acnes* tested. The most active fractions were 649C-F9 and 649C-F13, with IC~50~ values ranging from 4 to 32 μg ml^−1^ and MIC values ranging from 16 to 32 μg ml~-~ ^1^ across all isolates ([**Table 4**](#T4){ref-type="table"} and [**Figure 6**](#f6){ref-type="fig"}). Although no interpretive standards from the CLSI for antibiotic resistance exist for *C. acnes*, it is noteworthy that seven of the nine clinical isolates tested exhibited MICs \>4 μg ml^−1^ for the antibiotic control (clindamycin), which is commonly used in both oral and topical therapies for the management of acne vulgaris. Furthermore, six of the nine clinical isolates tested did not achieve even 50% growth inhibition at the maximum concentration of clindamycin tested (4 μg ml^−1^).

![Fractions of 649C were screened at 64 µg ml^−1^ to determine which ones exhibited the most growth inhibitory activity against *C. acnes* strain ATCC6919. Fractions exhibiting \>90% growth inhibition and the parent extracts 649 and 649C (*green bars*) were further tested for growth inhibition dose--response assay, biofilm eradication, and cytotoxicity against human skin cells. The *blue bars* represent the least active fractions. Clindamycin was used as a positive antibiotic control (*pink bar*).](fphar-10-01206-g003){#f3}

![**(A)** Growth inhibitory activity, **(B)** biofilm eradication, and **(C)** cytotoxicity on human keratinocytes (HaCaTs) of *C. americana* crude extract and the most active fractions. Tested fraction concentrations ranged from 0.25 to 64 µg ml^−1^, from 0.5 to 394 µg ml^−1^, and from 2 to 1,024 µg ml^−1^ for growth inhibition, biofilm eradication, and cytotoxicity assays, respectively. *Points* represent means and *bars* are standard error of the mean. *Dotted lines* represent 50% and 90% thresholds.](fphar-10-01206-g004){#f4}

![Growth inhibitory activity of extracts and fractions against a panel of nine clinical isolates of *C. acnes*.](fphar-10-01206-g005){#f5}

###### 

*C. americana* extract, partition, and fraction growth inhibition (IC~50~ and MIC) and HaCat cytotoxicity IC~50~ values (in µg ml^−^ ^1^).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 649       649C      649C-F8   649C-F9   649C-F12   649C-F13   649C-F14   649C-F15   649C-F17   649C-F19   649C-F21   649C-F22   Cli-
  ---------------------------- ----------------- --------- --------- --------- --------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- --------
  **IC~50~ for *C. acnes***\   **ATCC6919**      32        32        16        8         16         16         16         16         16         16         16         16         0.0625
  **growth**                                                                                                                                                                     

  **B104.1**                   64                16        32        16        32        8          8          8          32         32         32         32         \>4        

  **B104.2**                   64                32        32        32        32        8          16         16         32         32         32         32         \>4        

  **B104.4**                   64                16        64        8         32        8          16         16         32         32         32         32         \>4        

  **B104.5**                   32                16        32        16        32        4          8          8          32         32         32         32         \>4        

  **B104.6**                   64                32        64        16        64        16         32         32         64         64         64         64         0.5        

  **B104.7**                   \>64              64        64        16        64        16         64         64         \>64       64         64         64         0.5        

  **B104.8**                   64                16        32        8         32        8          16         16         32         32         32         32         \>4        

  **EU-09**                    \>64              32        64        16        64        16         32         32         64         64         64         32         \>4        

  **EU-16**                    64                32        32        16        32        8          16         8          8          8          16         16         \< 0.125   

  **MIC for *C. acnes***\      **ATCC6919**      \>32      \>32      32        16        16         16         32         32         16         16         16         16         \>8
  **growth**                                                                                                                                                                     

  **B104.1**                   64                32        64        32        64        16         32         32         64         64         64         64         \>4        

  **B104.2**                   64                32        64        32        64        16         64         32         64         64         64         64         \>4        

  **B104.4**                   64                32        64        16        64        16         64         32         64         64         64         64         \>4        

  **B104.5**                   64                32        64        32        64        16         32         32         64         64         64         32         \>4        

  **B104.6**                   64                32        \>64      16        64        16         64         64         \>64       64         64         64         0.5        

  **B104.7**                   \>64              64        \>64      16        64        32         64         64         \>64       64         64         64         1          

  **B104.8**                   \>64              32        64        16        64        16         32         32         64         64         64         32         \>4        

  **EU-09**                    \>64              64        \>64      16        64        16         64         64         \>64       64         64         64         \>4        

  **EU-16**                    \>64              64        32        16        64        16         64         32         32         16         32         16         0.125      

  **HaCat**                    **IC** **~50~**   \> 1024   \> 1024   128       256       \>512      \>512      \> 1024    \> 512     512        \>512      \>512      1024       --

  **TI**                       **Lower range**   16        32        2         8         8          32         16         8          8          8          8          16         --

  **Upper range**              \>32              \>64      8         32        32        128        128        64         64         64         32         64         --         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All values were determined as compared to the vehicle control for at least three replicates. The therapeutic index (TI) is reported as a range of values for the 10 C. acnes isolates (cytotoxicity IC~50~ divided by growth inhibition IC~50~).

Cli clindamycin, antibiotic control.

![Growth inhibitory activity of the most active fractions and their parent extracts against a panel of nine clinical isolates of *C. acnes*.](fphar-10-01206-g006){#f6}

Biofilm Eradication Activity in *C. acnes* {#s3_2}
------------------------------------------

Biofilm eradication activity was assessed, and none of the fractions were found to significantly eradicate the biofilm. A decrease in 30--40% of biofilm was observed for the highest concentration tested (394 μg ml^−1^). Resveratrol, a previously reported candidate for *C. acnes* biofilm eradication, reached 30% eradication at a concentration of 394 μg ml^−1^.

*C. americana* Extracts Exhibit Low Toxicity to Human Keratinocytes {#s3_3}
-------------------------------------------------------------------

To examine possible cytotoxic effects of the extracts in mammalian cells, HaCaT cells were treated at concentrations ranging from 2 to 1,024 μg ml^−1^. For all tested fractions, cytotoxicity (IC~50~) was only observed at more than eight times the dose required for inhibitory activity when compared to the IC~50~ values for *C. acnes* strain ATCC6919 ([**Table 4**](#T4){ref-type="table"}). Fractions 649C-F8 and 649C-F9 were the most cytotoxic to the HaCaTs, with IC~50~ values at 28 and 256 μg ml^−1^, respectively. The therapeutic index (TI) was calculated by dividing the IC~50~ for mammalian cytotoxicity by the IC~50~ for *C. acnes* growth inhibition, and the TI range for each fraction is reported in [**Table 4**](#T4){ref-type="table"}.

Chemical Characterization of Extracts {#s3_4}
-------------------------------------

The LC-FTMS ESI-positive mass spectral chromatograms of the ethyl acetate partition (649C) and the bioactive fractions (649C-F9 and 649C-F13) are shown in [**Figure 7**](#f7){ref-type="fig"}. The ions with greater than a 1% abundance in the LC-FTMS ESI-positive mode analysis are tabulated in [**Table 5**](#T5){ref-type="table"}. Fraction 649C-F9 is the least complex fraction, with over 56% consisting of a compound with *m*/*z* 637.4457 eluting at 51.3 min. A total of nine ions were identified as having greater than 1% relative abundance. Putative matches were only obtained for peak number **1** with an empirical formula of C~20~H~29~O~3~, which corresponded to 14 compounds in Scifinder: 16ξ-hydroxycleroda-3,11(E),13-trien-15,16-olide (CAS \#**935527-99-4**), seco-hinokiol (**834870-61-0**), angustanoic acid F (**104998-60-9**), 7-hydroxydehydroabietic acid (**95416-24-3**), 11-hydroxylsugiol (**88664-08-8**), 3,4-dihydroxyphenethyl glucoside (**76873-99-9**), 7α-hydroxydehydroabietic acid (**76235-98-8**), 7β-hydroxydehydroabietic acid (**73609-55-9**), 15- hydroxydehydroabietic acid (**54113-95-0**), maingayic acid (**34327-14-5**), 11-hydroxy-13-(1-hydroxy-1-methylethyl)-podocarpa-8,11,13-trien-7-one (**16755-58-1**), 11-hydroxy-12-methoxyabietatriene (**16755-54-7**), methyl trans-communate (**15798-13-7**), and methyl isopimarate (**1686-62-0**).

![HPLC-FTMS ESI-positive chromatograms for **(A)** 649C, **(B)** 649C-F9, and **(C)** 649C-F13. Peaks **1**--**6** are indicated.](fphar-10-01206-g007){#f7}

###### 

Tabulated (M+H)**^+^** ions, empirical formulas, for the bioactive 649C fractions.

  Peak number             Retention time (min)   *m/z*                              Relative abundance (%)   Empirical formula Δ (ppm)
  ----------------------- ---------------------- ---------------------------------- ------------------------ ---------------------------
  **Fraction 649C-F9**                                                                                       
                          33                     371.0991                           1.4                      C~16~H~19~O~10~ (4.7)
                          39.8                   376.2581                           15.49                    C~23~H~36~O~4~ (−6.8)
                          42.1                   368.2422                           7.55                     C~17~H~36~O~8~ (5.2)
                          43.4                   368.2426                           8.19                     C~17~H~36~O~8~ (5.9)
                          46.5                   718.449                            5.73                     C~37~H~66~O~13~ (−1.1)
                          48.2                   371.0994                           0.92                     C~19~H~17~O~7~N (−1.6)
  **1**                   50.3                   **317.2099**, 650.4375             2.89                     C~20~H~29~O~3~ (−3.8)
                          51.3                   637.4457                           56.4                     C~40~H~61~O~6~ (−1.0)
                          60.6                   630.504                            1.24                     C~36~H~70~O~8~ (−4.0)
  **Fraction 649C-F13**                                                                                      
                          24.2                   608.3806                           2.09                     C~30~H~56~O~12~ (6.5)
                          30.6                   371.0994                           1.66                     C~16~H~19~O~10~ (5.7)
                          30.9                   371.0993                           1.04                     C~16~H~19~O~10~ (5.5)
                          38.0                   384.2368                           7.89                     C~17~H~36~O~9~ (3.7)
                          40.2                   384.2374, 782.4683                 2.23                     C~38~H~70~O~16~ (2.8)
  **2**                   41.1                   376.2583                           6.92                     C~23~H~36~O~4~ (−6.8)
                          41.6                   715.4025                           6.76                     C~40~H~59~O~11~ (−3.8)
                          43.5                   718.4499                           1.39                     C~37~H~66~O~13~ (0.2)
                          44.9                   718.4499                           1.01                     C~37~H~66~O~13~ (−1.5)
  **3**                   45.8                   301.2152                           1.48                     C~20~H~29~O~2~ (−3.5)
  **4**                   47.5                   **303.2309**, 605.4541, 750.4388   1.52                     C~20~H~31~O~2~ (−3.3)
  **5**                   47.7                   **305.2464**, 609.4851             1.64                     C~20~H~33~O~2~ (−3.5)
                          49.6                   669.4379                           36.27                    C~40~H~61~O~8~ (2.7)
  **6**                   50.9                   **319.2257**, 659.4258             2.03                     C~20~H~31~O~3~ (−3.3)
                          51.7                   654.4701                           1.51                     C~37~H~66~O~9~ (0)
                          63.5                   621.302                            6.87                     C~43~H~41~O~4~ (3.2)
                          64.5                   621.3017                           4.05                     C~43~H~41~O~4~ (2.8)
                          67.2                   621.3037                           2.19                     C~36~H~45~O~9~ (−3.4)
                          76.3                   371.0991                           5.02                     C~16~H~19~O~10~ (5.0)

ND, formula not determined.

\*Percent relative abundance is determined by peak area.

^†^The putative formula is reported for bold ion.

Fraction 649-F13 was more diverse, with 19 ions having greater than 1% relative abundance by LC-MS analysis. As before, a single ion dominates, *m/z* 669.4379 eluting at 49.6 min. There are no putative matches for this ion in Scifinder. However, putative matches were obtained for five other ions from 649C-F13, identified as peaks **2--6** in [**Figure 7**](#f7){ref-type="fig"}. Peak **2** has *m/z* 376.2583 and empirical formula C~23~H~36~O~4~ and corresponds to \[5′aS-(5′aα,7′aα,9′α,10′α,12′aα,12′bβ)\]-decahydro-2,2,5′,5′,12′b-pentamethyl-spiro\[1,3-dioxolane-4,9′(8′H)-\[7a,10\]methano\[7aH\]cyclohepta\[g\]\[2\]benzoxepin\]-3′(2′H)-one (CAS \#**49817-39-2**). Peak **3** has *m/z* 301.2152 and empirical formula C~20~H~29~O~2~ which corresponds to (5α,9α,10β)-3-oxo-kaur-15-en-17-al (CAS \#**878000-26-1**), 18-oxoferruginol (**108904-92-3**), 4-epidehydroabietic acid (**5155-70-4**), and dehydroabietic acid (**1740-19-8**). Peak **4** has *m/z* 303.2309 and empirical formula C~20~H~31~O~2~ and corresponds to callicarpic acid A (CAS \#**1130124-82-1**), 1-\[2-(3-furanyl)ethyl\]-1,3,4,7,8,8a-hexahydro-1,2,5-trimethyl-4a(2*H*)-naphthalenemethanol (**35319-12-1**), isopimaric acid (**5835-26-7**), and cryptopimaric acid (**471-74-9**). Peak **5** has *m/z* 305.2464 and empirical formula C~20~H~33~O~2~ which corresponds to \[4a*S*-(4aα,4bβ,8aα,10aβ)\]-4a,4b,5,6,7,8,8a,9,10,10a-decahydro-2-(1-hydroxy-1-methylethyl)-4b,8,8-trimethyl-4(1*H*)-phenanthrenone (CAS \#**121926-95-2**), \[1R-(1α,4aβ,4bα,7α,8α,10aα)\]-7-ethenyl-1,2,3,4,4a,4b,5,6,7,8,10,10a-dodecahydro-8-hydroxy-1,4a,7-trimethyl-1-phenanthrenemethanol (**101467-73-6**), 15,16-dihydroisopimaric acid (**5673-36-9**), 15,16-dihydrosandaracopimaric acid (**4807-69-6**), and arachidonic acid (**506-32-1**). Peak **6** has *m/z* 319.2257 and empirical formula C~20~H~31~O~3~ and corresponds to 4-\[2-\[(1S,4aR,6S,8aR)-1,4,4a,5,6,7,8,8a-octahydro-6-hydroxy-2,5,5,8a-tetramethyl-1-naphthalenyl\]ethyl\]-2(5H)-furanone (CAS \#**2305691-63-6**), 4-\[2-\[(1S,4aR,6S,8aR)-decahydro-6-hydroxy-5,5,8a-trimethyl-2-methylene-1-naphthalenyl\]ethyl\]-2(5H)-furanone (**2305691-62-5**), nudiflopene B (**2226250-84-4**), (1S, 4aS, 4bS, 7S, 8S, 10aS)-7-ethenyl-1, 2, 3, 4, 4a, 4b, 5, 6, 7, 8, 10, 10a-dodecahydro-8-hydroxy-1, 4a,7-trimethyl-1-phenanthrenecarboxylic acid (**2137490-87-8**), callilongisin D (**1367097-06-0**), callilongisin C (**1367097-03-7**), callilongisin B (**1367097-00-4**), (1S,2S,8aS)-1,2,3,7,8,8a-hexahydro-8a-hydroxy-1-methyl-2-(1-methylethenyl)-6-(1-methylethyl)-1-naphthalenepropanoic acid (**1123207-97-5**), 12(S)-hydroxycleroda-3, 13-dien-16, 15-olide (**935293-68-8**), 12(S)-hydroxycleroda-3, 13-dien-15,16-olide (**935293-66-6**), 16ξ-hydroxycleroda-3,13-dien-15,16-olide (**141979-19-3**), 7α-hydroxysandaracopimaric acid (**122537-68-2**), \[4aS-(4aα,7aα,8aα,9bβ)\]-2, 3, 4, 4a, 5, 6, 7, 7a, 8a, 9b-decahydro-7a-(1-hydroxy-1-methylethyl)-4,4,9b-trimethyl-phenanthro\[2,3-b\]oxiren-9(1H)-one (**121926-98-5**), calliphyllin (**101467-72-5**), and 3-oxoanticopalic acid (**83997-21-1**).

Discussion {#s4}
==========

The most active fractions of the *C. americana* leaf extracts exhibited MICs against *C. acnes* isolates at concentrations as low as 0.016 mg ml^−1^, which is 30 times less than the lowest MIC value found for other botanical extracts previously investigated, including Jeju (*Thymus quinquecostatus* Celak., Lamiaceae---MIC of 0.5 mg ml^−1^), Damask Rose (*Rosa* x *damascene* Herrm., Rosaceae---MIC of 2 mg ml^−1^), Duzhong (*Eucommia ulmoides* Oliv., Eucommiaceae---MIC of 0.5 mg ml^−1^), and Maté (*Ilex paraguariensis* A.St.-Hil.---MIC of 1 mg ml^−1^) ([@B22]; [@B35]). In comparison to the growth inhibition activity, the *C. americana* extracts were less effective at the eradication of existing biofilm. Following the result reported by Coenye *et al.*, we included resveratrol as a biofilm eradication control ([@B4]). At the highest concentration tested (394 μg ml^−1^), only 21% inhibition was achieved by resveratrol. However, the previous 80% biofilm eradication reported for resveratrol was at a concentration of 3,200 μg ml^−1^.

The cytotoxicity (IC~50~) of the most active fractions, 649C-F9 and 649C-F13, were at concentrations 32 and \>128 times greater than that required for *C. acnes* growth inhibition (IC~50~). These results demonstrate the strong potential of *C. americana* fractions to reduce *C. acnes* fitness at a good therapeutic index ratio of mammalian toxicity to antimicrobial activity.

In other studies, bioassay-guided fractionation of the dried leaf, twigs, and fruits of *C. americana* extracts led to the isolation of six clerodane diterpenes ([@B10]). Flavonoids including genkwanin, 5-hydroxy-7,4′-dimethoxyflavone, and luteolin were also found in these extracts. The leaf essential oil contained lipids \[(E)-2-hexenal and 1-octen-3-ol\] as well as monoterpenoids (nopinone, α-pinene, and β-pinene), sesquiterpenoids (α-cadinol, caryophyllene oxide, 7-*epi*-α-eudesmol, α-humulene, humulene epoxide II, intermediol, khusinol, valencene, α-selinene, and 7-*epi*-α-selinene), and triperpenoids (euscaphic acid) ([@B30]; [@B13]; [@B3]; [@B10]). Some compounds were active against human cancer cell lines with a cytotoxic activity below 5 µg ml^−1^. These include 12(*S*),16-dihydroxycleroda-3,13-dien-15,16-olide, 2-formyl-16-hydroxy-3-α-norcleroda-2,13-dien-15,16-olide, genkwanin, 12(*S*)-hydroxycleroda-3,13-dien-16,15-olide, 16-hydroxycleroda-3,13-dien-15,16-olide, and 16-hydroxy-cleroda-3,11(*E*),13-trien-15,16-olide. Intermedeol and callicarpenal were demonstrated to be effective deterrents of *A. stephensi* and *A. aegypti* mosquitos, and clerodane diterpenes are also known to have insect antifeedant properties ([@B7]). To the best of the authors' knowledge, this is the first report on the antibacterial activity of *C. americana* extracts against *C. acnes*.

By colonizing the pilosebaceous follicle and inducing the production of reactive oxygen species highly toxic to the cells ([@B27]), *C. acnes* exacerbates the inflammation associated with acne vulgaris. *C. acnes* also worsens the symptoms by inducing immune cells to produce pro-inflammatory cytokines including interleukins and tumor necrosis factors ([@B38]). Prior studies on ethanolic extracts of rosemary demonstrated a significant reduction of cytokine production *in vitro* and attenuation of swelling and inflammation in a mouse model ([@B35]). The minimum inhibitory concentration was 4 mg ml^−1^, which is 250 times more than the lowest MIC reported in the present paper. By effectively reducing *C. acnes* growth and proliferation, *C. americana* leaf extracts may also impact inflammatory processes. Further research is needed to evaluate this aspect of *C. americana* treatments with *in vivo* infection models.

While treating acne with antibiotics, such as erythromycin and clindamycin, was shown to significantly reduce inflammation, extensive use of oral and/or topical antibiotics since the 1960s has led to the emergence of resistant strains ([@B6]). This underlines the need for alternative compounds for acne therapy. Other factors such as androgens, poor digestion, or smoking habits ([@B15]) are also important in the development and persistence of the disease. Treatments should focus not only on the consequences but also on the causes of acne and could combine cross-acting compounds to reduce sebum production, correct stomach acidity for better digestion, while also reducing inflammation ([@B41]). Previous studies reported the interesting potential of botanical combinations in treatments to reduce acne ([@B14]; [@B12]). Our study highlights the potential of *C. americana* leaf extracts to efficiently reduce bacterial proliferation and lessen acne vulgaris symptoms.

Conclusion {#s5}
==========

Our work has demonstrated the promising antibacterial potential of *C. americana* constituents against *C. acnes* growth. Fractions 649C-F9 and 649C-F13 exhibited growth inhibitory activity against a panel of 10 C. *acnes* isolates and with a good therapeutic index of 32 and \>128, respectively). Future studies should pursue isolation and structural determination of active components, further examination of the efficacy and safety of the compounds, and examine the mechanism of action for these observed antibacterial effects.
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